Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure

Journal of Molecular and Cellular Cardiology

Volumn 33, Issue 5, 2001, Pages 887-905

  Port, J David ^a   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Gene regulation; Heart failure; Signal transduction; adrenergic receptor

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC TRANSMISSION; APOPTOSIS; BETA ADRENERGIC RECEPTOR BLOCKING; BETA ADRENERGIC STIMULATION; CONGESTIVE HEART FAILURE; DISEASE COURSE; GENE CONTROL; GENE OVEREXPRESSION; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE RELAXATION; HEART RATE; HEART STRESS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034976707     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2001.1358     Document Type: Article

References (191)

1. Beta-adrenergic pathways in non-failing and failing human ventricular myocardium
2. Adrenergic effects on the biology of the adult mammalian cardiocyte
3. Adrenergic nervous system in heart failure
4. Changes in myocardial and vascular receptors in heart failure
5. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure
6. Observations on the intracoronary, administration of milrinone and dobutamine to patients with congestive heart failure
7. Interactions between phospholamban and b-adrenergic drive may lead to cardiomyopathy and early mortality
8. Effects of pressure overload, left ventricular hypertrophy on beta-adrenergic receptors, and responsiveness to catecholamines
9. Uber die Wirkung intravenoser adrenalin-injektion auf das Gefafssytem und ihre Beziehung zur Arteriosklerose
10. Catecholamine cardiotoxicity
11. Cellular and ventricular contractile dysfunction in experimental canine mitral regurgitation
12. Physiological and molecular correlates of age-related changes in the human beta-adrenergic receptor system
13. Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations
14. Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy?
15. Reduced Ca(2 +)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation
16. A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta-agonists
17. Regulatory role of phospholamban in the efficiency of cardiac sarcoplasmic reticulum Ca(2 +) transport
18. Maximal inhibition of SERCA2 Ca(2 +) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban
19. Phospholamban and cardiac contractile function
20. Cardiac Gsalpha overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway
21. Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway
22. Beta-adrenergic receptor blockade in chronic heart failure
23. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure
24. Development of the concept of alpha and beta adrenotropic receptors
25. Functional significance of presynaptic alpha-adrenergic receptors in failing and nonfailing human left ventricle
26. Alpha 2C-adrenoceptor-modulated release of noradrenaline in human right atrium
27. The alpha(1)-adrenoceptor subtype- and protein kinase C isoform-dependence of Norepinephrine's actions in cardiomyocytes
28. Protein kinase C isoform diversity in the heart
29. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle
30. Functional beta3-adrenoceptor in the human heart
31. Action potential shortening through the putative beta4-adrenoceptor in ferret ventricle: Comparison with beta1- and beta2-adrenoceptor-mediated effects
32. Identification of cardiac beta-adrenergic receptors by (-) [3H]alprenolol binding
33. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure
34. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts
35. The functional importance of beta 1 and beta 2 adrenoceptors in the human heart
36. Pathophysiology of the beta-adrenoceptor system in chronic heart failure: Consequences for treatment with agonists, partial agonists or antagonists?
37. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium
38. Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy
39. G protein-coupled receptor kinases
40. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart
41. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart
42. Differentiation of receptor systems activated by sympathomimetic amines
43. A quantitative study of beta-adrenergic receptors in rabbit atria
44. Treatment of Heart Failure: Pharmacological Methods
45. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes
46. Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins
47. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A
48. Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i)
49. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy
50. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart
51. The role of G-proteins in transduction of the beta-adrenergic response in heart failure
52. G proteins and cardiovascular disease
53. The {beta}2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3′-kinase
54. Physiological regulation of G protein-linked signaling
55. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase
56. AKAPs: From structure to function
57. Assembly of an A kinase-anchoring protein-beta(2)-adrenergic receptor complex facilitates receptor phosphorylation and signaling
58. Dynamic complexes of beta2-adrenergic receptors with protein kinases and phosphatases and the role of gravin
59. cAMP-dependent regulation of cardiac L-type Ca2 + channels requires membrane targeting of PKA and phosphorylation of channel subunits
60. Identification of the endophilins (SH3p4/p8/p13) as novel binding partners for the beta1-adrenergic receptor
61. Beta 1-adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of beta 1-adrenergic receptor interaction with N-methyl-D-aspartate receptors
62. Lack of spare beta-adrenergic receptors in the human heart
63. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response
64. --dependent intracellular alkalinization
65. 2+ dynamics, contractility, or phospholamban phosphorylation
66. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes
67. Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes
68. Recent advances in cardiac beta(2)-adrenergic signal transduction
69. 2+ current in single rat ventricular cells
70. Localized cAMP-dependent signaling mediates beta 2-adrenergic modulation of cardiac excitation-contraction coupling
71. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways
72. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: An apoptosis-independent model of dilated heart failure
73. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy
74. Calcineurin and beyond: Cardiac hypertrophic signaling
75. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy
76. Phosphorylation of the mammalian beta-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein
77. Phosphorylation and desensitization of the human β1-adrenergic receptor. Involvement of G-protein-coupled receptor kinases and cAMP-dependent protein kinase
78. Role of beta gamma subunits of G proteins in targeting the beta-adrenergic receptor kinase to membrane-bound receptors
79. Pleckstrin homology domain-mediated membrane association and activation of the beta-adrenergic receptor kinase requires coordinate interaction with G beta gamma subunits and lipid
80. Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase. cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms
81. The role of receptor kinases and arrestins in G protein-coupled receptor regulation
82. Desensitization of G-protein-coupled receptors in the cardiovascular system
83. Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors
84. Differential targeting of beta-adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway
85. Mechanisms of beta-adrenergic receptor desensitization and resensitization
86. Distinct regulation of β1- and β2-adrenergic receptors in Chinese hamster fibroblasts
87. Distinct receptor domains determine subtype-specific coupling and desensitization phenotypes for human beta1- and beta2-adrenergic receptors
88. A proline-rich region of the third intracellular loop imparts phenotypic beta 1- versus beta 2-adrenergic receptor coupling and sequestration
89. The β-Adrenergic pathway mediates norepinephrine-stimulated apoptosis in vitro in adult rat cardiac myocytes
90. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway
91. Gi protein protects adult rat ventricular myocyctes, from β-adrenergic receptor-stimulated apoptosis in vitro
92. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein
93. p38 mitogen activated protein kinase pathway protects adult rat ventricular myocytes against beta-adrenergic receptor stimulated apoptosis: Evidence for Gi dependent activation
94. Beta2-adrenergic receptor-selective agonist clenbuterol prevents Fas-induced liver apoptosis and death in mice
95. Persistent stimulation of β-adrenergic signaling triggers degeneration and apoptosis of cardiomyocytes
96. Apoptotic signaling through the beta-adrenergic receptor. A new Gs effector pathway
97. Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes
98. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice
99. Apoptosis of cardiac myocytes in Gsalpha transgenic mice
100. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse
101. Beta-adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes
102. Evidence for norepinephrine cardiotoxicity mediated by superoxide anion radicals in isolated rabbit hearts
103. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction
104. Adrenergic hormones and control of cardiac myocyte growth
105. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
106. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
107. Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches
108. Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium
109. Dynamic changes in the expression of contractility-regulating genes in the failing human heart associated with improvement of deterioration in ventricular systolic function
110. A cAMP response element in the beta 2-adrenergic receptor gene confers transcriptional autoregulation by cAMP
111. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium
112. Cloning of the cDNA for the human β1-adrenergic receptor
113. Cloning and sequence analysis of the human beta 1-adrenergic receptor 5′-flanking promoter region
114. Thyroid hormones transcriptionally regulate the beta 1-adrenergic receptor gene in cultured ventricular myocytes
115. Glucocorticoids down-regulate beta 1-adrenergic-receptor expression by suppressing transcription of the gene
116. Identification of a glucocorticoid repressor domain in the rat beta 1-adrenergic receptor gene
117. Identification of a retinoic acid response domain involved in the activation of the beta 1-adrenergic receptor gene by retinoic acid in F9 teratocarcinoma cells
118. Glucocorticoid induction of beta-adrenergic receptors in the DDT1 MF-2 smooth muscle cell line involves synthesis of new receptor
119. Identification of a glucocorticoid response element in the rat beta2-adrenergic receptor gene
120. Thyroid hormone induces beta1-adrenergic receptor gene transcription through a direct repeat separated by five nucleotides
121. Reduced β1 receptor messenger RNA abundance in the failing human heart
122. Beta 1- and beta 2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure
123. Adrenergic regulation of ICER (inducible cyclic AMP early repressor) and β1-adrenergic receptor gene expression in C6 glioma cells
124. Agonist-induced destabilization of β-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of β-adrenergic receptors
125. Down-regulation of β-adrenergic receptors: Agonist-induced reduction in receptor mRNA levels
126. Agonist regulation of human β2-adrenergic receptor mRNA stability occurs via a specific AU-rich element
127. Agonist-mediated destabilization of human beta1-adrenergic receptor mRNA: Role of the 3′ untranslated translated region
128. Regulation of the mRNA-binding protein AUF1 by activation of the β-adrenergic receptor signal transduction pathway
129. Purification and characterization of beta-adrenergic receptor mRNA-binding proteins
130. Adhesion-dependent regulation of an ARE-binding activity associated with AUF1
131. HuR regulates p21 mRNA stabilization by UV light
132. Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway
133. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation
134. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism
135. The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits synthesis
136. Enhances myocardial function in transgenic mice overexpressing the β2-adrenergic receptor
137. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: Critical role for expression level
138. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice
139. Functional consequences of altering myocardial adrenergic receptor signaling
140. Intrinsic receptor activity of β1-adrenoceptors overexpressed in rat ventricular cardiac myocytes
141. Overexpression of myocardial Gsalpha prevents full expression of catecholamine desensitization despite increased beta-adrenergic receptor kinase
142. Depressed heart rate variability and arterial baroreflex in conscious transgenic mice with overexpression of cardiac Gsalpha
143. Localisation of cardiac GS alpha in transgenic mice overexpressing GS alpha
144. Cardiomyopathy induced by cardiac Gs alpha overexpression
145. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression
146. Overexpression of Gs alpha protein in the hearts of transgenic mice
147. Myocardial Gsα overexpression reveals disparate pathways in regulation of inotropy vs. lusitropy in isolated myocytes
148. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a βARK inhibitor
149. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation
150. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy
151. Xamoterol in severe heart failure
152. Effect of oral milrinone on mortality in severe chronic heart failure
153. Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-over-expressing mice
154. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice
155. Differential patterns of gene expression in development and rescue of mouse heart failure
156. Targeted disruption of the mouse β1-adrenergic receptor gene: Developmental and cardiovascular effects
157. Targeted disruption of the beta2 adrenergic receptor gene
158. Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors
159. Spontaneous activation of beta(2)- but not beta(1)-adrenoceptors expressed in cardiac myocytes from beta(1)beta(2) double knockout mice
160. Rationale for beta-adrenergic blocking drugs in cardiomyopathy
161. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy
162. Heart failure 99 - The MOXCON story
163. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure
164. The effects of moxonidine, a novel imidazoline, on plasma norepinephrine in patients with congestive heart failure
165. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
166. Differential effects of β-blocking agents on adrenergic activity
167. The effect of beta-adrenergic blockade on mortality in patients with advanced chronic heart failure: The beta-blocker evaluation of survival trial (BEST)
168. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure
169. Genetic polymorphisms of the human β2-adrenergic receptor (β2AR) predict survival in patients with heart failure
170. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice
171. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: Analysis of c145A>G and c1165G>C
172. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression
173. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor
174. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors
175. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure
176. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor
177. Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy
178. Polymorphic Gly389 β1 adrenergic receptors depress exercise capacity in heart failure
179. Hierarchy of genotype and desensitization permutations on b1-adrenergic receptor signaling
180. Design of the Beta-Blocker Evaluation Survival Trial (BEST)
181. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy
182. A comparison of gene expression in failing and non failing human left ventricular tissue
183. Gene expression informatics - It's all in your mind
184. Differential activation of p38 mitogen-activated protein kinase isoforms depending on signal strength
185. The MEK1ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
186. The cellular actions of ss-adrenergic receptor agonists: Looking beyond cAMP
187. Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy
188. Beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by PKA rather than by Gi or Gbeta gamma in adult mouse cardiomyocytes
189. Dual modulation of cell survival and cell death by beta 1-adrenergic signaling in adult mouse cardiac myocytes
190. β-Adrenergic cardiac hypertrophy is mediated primarily by the β1-subtype in the rat heart
191. Manipulations of cardiac adrenergic signaling and calcium cycling have markedly different effects on the progression of cardiomyopathy